Results 51 to 60 of about 3,797 (192)
Interdisciplinary Perspectives on Infectious Diseases, Volume 2026, Issue 1, 2026.Trypanosomatids, including the genera Trypanosoma and Leishmania, are protozoan parasites of significant medical and veterinary relevance. These organisms cause African trypanosomiasis, Chagas disease, and leishmaniasis, which are classified as neglected tropical diseases (NTDs).
Cynthia Mmalebna Amisigo +13 more
wiley +1 more source
, 2017 Characteristics of genotype 4 hepatitis C patients treated with simeprevir plus sofosbuvir with or without ribavirin.
Hendrik Reynaert (3710233) +17 more
core +1 more source
Fatigue during treatment for hepatitis C virus : results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection [PDF]
, 2014 Background: Fatigue is a common symptom of chronic hepatitis C virus (HCV) infection and a frequent side-effect of peginterferon/ribavirin (PR) therapy for HCV.
Stefan Zeuzem +18 more
core +2 more sources
Egyptian Rheumatology and Rehabilitation, 2020 Background To study the most common rheumatologic manifestations of hepatitis C viral (HCV) infection in Egyptian patients and associated risk factors with assessment the effect of current therapies on these manifestations.
Hanan M. Fathi +6 more
doaj +1 more source
Журнал инфектологии, 2016 The protease inhibitors (PI) actively using for the treatment of chronic hepatitis C (CHC).The aim of this analysis was to evaluate the cost-effectiveness of narlaprevir and simeprevir in the CHC (genotype 1) therapy in treatment-naïve patients and ...
A. V. Rudakova +4 more
doaj
Virology Journal, 2018 Background Simeprevir is approved with pegylated interferon and ribavirin (PR) for chronic hepatitis C virus (HCV) genotype (GT) 1 and GT4 infection in the USA and the European Union.
Fabien Zoulim +11 more
doaj +1 more source
Liver International, Volume 45, Issue 10, October 2025.ABSTRACT Background and Aims Hepatitis C virus (HCV) is a key driver of hepatocellular carcinoma (HCC). However, the impact of HCV eradication on systemic therapy remains unclear. We aimed to assess the safety and efficacy of direct‐acting antivirals (DAA) in patients treated with Atezolizumab plus Bevacizumab (AtezoBev).
Leonardo Stella +30 more
wiley +1 more source
Терапевтический архив, 2014 Triple therapy with pegylated interferon-α, ribavirin, and simeprevir is now optimal among the antiviral treatment options available in the Russian Federation for patients with chronic hepatitis C (CHC), including in the compensated stage of liver ...
É Z Burnevich
doaj
Harnessing Viral Proteases for Cellular and Molecular Engineering
Chemistry–Methods, Volume 5, Issue 9, September 2025.Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui +2 more
wiley +1 more source
PGI28 Cost-Effectiveness of Simeprevir Vs. Telaprevir for The Triple Therapy of Hepatitis C In Kazakhstan [PDF]
, 2015 Hepatitis C Virus(HCV) is a growing health problem in the world. The aim of this study is to estimate a cost-effectiveness of a triple therapy(TT) with simeprevir compared to a TT with telaprevir for the previously treated with double therapy HCV ...
C, Bektur +3 more
core +1 more source